Skip to main content

Table 3 Multivariable analysis

From: Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine

 

Acute GvHD II–IV

Chronic GvHD

Relapse

NRM

LFS

OS

GRFS

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95%CI)

p

HR (95% CI)

p

Donor type

 SUCBT vs. Haplo

1.03 (0.56–1.89)

0.923

1.86 (0.70–4.95)

0.21

0.81 (0.32–2.04)

0.65

2.63 (1.44–4.83)

0.002

1.95 (1.20–3.16)

0.007

2.19 (1.31–3.65)

0.003

2.39 (1.51–3.79)

< 0.001

 Year of HSCT

0.97 (0.85–1.11)

0.677

0.91 (0.77–1.08)

0.30

0.93 (0.76–1.14)

0.50

1.01 (0.88–1.15)

0.925

0.98 (0.88–1.10)

0.772

1.00 (0.89–1.12)

1.000

1.07 (0.97–1.189)

0.197

 Age (per 10 years)

0.89 (0.72–1.08)

0.236

1.17 (0.93–1.47)

0.19

1.07 (0.80–1.42)

0.66

1.20 (0.99–1.47)

0.071

1.15 (0.98–1.35)

0.096

1.18 (0.99–1.40)

0.055

1.11 (0.96–1.29)

0.164

Karnofsky PS

 ≥ 90 vs. < 90

0.67 (0.35–1.31)

0.243

1.05 (0.44–2.55)

0.91

0.35 (0.15–0.81)

0.01

0.60 (0.33–1.09)

0.094

0.50 (0.31–0.81)

0.005

0.60 (0.36–1.00)

0.053

0.58 (0.36–0.92)

0.020

Disease status at HSCT

 CR2 vs. CR1

1.16 (0.68–1.98)

0.582

0.89 (0.44–1.79)

0.74

0.79 (0.34–1.84)

0.59

1.19 (0.70–1.20)

0.524

1.07 (0.69–1.66)

0.760

1.19 (0.76–1.87)

0.457

0.92 (0.61–1.39)

0.703

Female donor to male recipient

 Yes vs. No

1.63 (0.97–2.73)

0.064

1.15 (0.60–2.18)

0.67

1.25 (0.57–2.73)

0.58

1.84 (1.12–3.02)

0.016

1.67 (1.11–2.53)

0.014

1.67 (1.08–2.58)

0.020

1.55 (1.05–2.28)

0.027

 Center

 

0.935

 

< 0.001

 

0.94

 

0.262

 

0.924

 

0.278

 

0.206

  1. GvHD Graft-versus-host disease, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, GRFS GvHD-free relapse-free survival, CI confidence interval, SUCBT single umbilical cord blood transplantation, NTD-Haplo non-T cell depleted Haploidentical transplantation, HSCT hematopoietic stem cell transplantation, CR complete remission